GenSight Biologics (SIGHT) H1 2025 earnings summary

Executive summary

• Operating income fell sharply to €0.04M from €1.7M year-over-year, mainly due to lower research tax credit and the impact of rebate obligations on ATU revenues.

• Net loss increased to €7.0M from €5.8M year-over-year, with loss per share at €(0.05) versus €(0.07).

• R&D, sales & marketing, and G&A expenses all declined, reflecting cost control and focus on manufacturing transfer and regulatory milestones.

• Achieved an 8.3% reduction in operating cash outflow in H1 2025 compared to H1 2024 through optimized cash management.

• Cash runway extended to late Q4 2025 after €3.7M post-closing financing; further extension possible with Early Access Program revenue.

Financial highlights

• Revenue recognized solely from changes in refund liability and rebate obligations; no new product sales.

• H1 2025 revenues were €0.1M, down from €1.1M in H1 2024.

• R&D expenses dropped 31.8% to €4.3M; G&A fell 10% to €2.3M; sales & marketing down 12.8% to €0.2M.

• Cash and cash equivalents at €0.3M as of June 30, 2025, down from €2.5M at year-end 2024.

• Net cash used in operations was €2.5M, with €0.3M net cash from financing activities in H1 2025.

Outlook and guidance

• Cash runway expected to last into late Q4 2025; could extend to May 2026 if French Early Access Program launches as planned.

• Additional financing may be needed if regulatory approval for the dose-ranging study is delayed.

• Medium-term funding strategy includes non-dilutive (EAP, licensing) and dilutive (equity) sources.